Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Oral Solid Dosage Pharmaceutical Formulation Market Growth Potential: How Will Market Size Shift Through 2030?
The oral solid dosage pharmaceutical formulation market size has shown significant growth in recent years. It is anticipated to expand from $653.26 billion in 2025 to $692.14 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.0%. The expansion observed historically can be attributed to factors such as the broad acceptance of oral drug delivery, a well-established manufacturing infrastructure for tablets and capsules, the increasing prevalence of chronic diseases, the cost-effectiveness of oral solid dosage forms, and strong regulatory familiarity with oral formulations.
The oral solid dosage pharmaceutical formulation market size is anticipated to experience robust expansion in the coming years. It is projected to reach $846.38 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 5.2%. This projected expansion during the forecast period is driven by several factors, including the escalating demand for long-acting oral drugs, a heightened emphasis on patient compliance and ease of use, the increasing scope of pharmaceutical outsourcing and CDMO services, the global rise in generic drug manufacturing, and advancements in excipients and formulation techniques. Key trends anticipated during this period encompass the increasing integration of controlled and modified-release dosage forms, a surging preference for convenient oral solid formats for patients, the expansion of both generic and branded solid dosage production, a heightened concentration on formulations with high bioavailability, and a move towards more cost-effective and scalable oral dosage manufacturing methods.
Get A Free Sample Report With In-Depth Market Insights:
Oral Solid Dosage Pharmaceutical Formulation Market Demand Drivers Opening New Revenue Streams
The rising occurrence of chronic illnesses is anticipated to boost the expansion of the oral solid dosage pharmaceutical formulation market in the future. These enduring health conditions are defined as ailments that persist over an extended duration, usually for at least three months. Their increase can be attributed to elements like an aging demographic, inactive routines, inadequate eating patterns, environmental influences, and enhanced methods of identification and diagnosis. Oral solid dosage pharmaceutical formulations play a crucial role in managing chronic diseases and fostering compliance with extended treatment plans, owing to their ease of use, stability, and accurate dosage. For example, in February 2024, the World Health Organization, an intergovernmental body situated in Switzerland, estimated that more than 35 million new cancer diagnoses are expected by 2050, marking a 77% rise from the approximately 20 million cases reported in 2022. Consequently, the growing frequency of chronic health conditions stimulates the growth of the oral solid dosage pharmaceutical formulation market.
Oral Solid Dosage Pharmaceutical Formulation Market Segment Performance And Emerging Opportunities
The oral solid dosage pharmaceutical formulation market covered in this report is segmented –
1) By Dosage Form: Tablets, Capsules, Powders And Granules, Lozenges And Pastilles, Gummies
2) By Mechanism: Controlled-Release, Immediate-Release, Delayed-Release
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, Hypermarkets Or Supermarkets
4) By End-User: Large-Size Companies, Medium And Small-Size Companies, Other End-Users
Subsegments:
1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets, Controlled-Release Tablets, Effervescent Tablets, Chewable Tablets, Sublingual Tablets
2) By Capsules: Hard Gelatin Capsules, Soft Gel Capsules, Liquid-Filled Capsules, Delayed-Release Capsules
3) By Powders And Granules: Oral Powders (Reconstitution), Granules (Oral Suspension Or Dispersible Granules)
4) By Lozenges And Pastilles: Medicinal Lozenges, Herbal Lozenges, Sugar-Free Lozenges, Pastilles ( Throat Or Cough Relief)
5) By Gummies: Vitamin Gummies, Herbal And Nutritional Supplement Gummies, Pharmaceutical Gummies ( Pain Relief Or Sleep Aids)
Oral Solid Dosage Pharmaceutical Formulation Market Trends Powering Strategic Industry Growth
Leading firms within the Oral Solid Dosage (OSD) pharmaceutical market are concentrating on creating novel approaches, including fixed dose combinations, to boost effectiveness, patient adherence, and safety. A fixed dose combination (FDC) refers to a drug product comprising two or more active pharmaceutical ingredients integrated into one dosage unit, aiming to streamline therapy and increase patient compliance. As an illustration, in February 2025, Ono Pharmaceutical Co. Ltd., a pharmaceutical entity based in Japan, obtained authorization from the U.S. Food and Drug Administration (FDA) for its Journavex (suzetrigine) 50 mg oral tablets, intended for managing moderate to severe acute pain in adults. This medication functions by specifically impeding NaV1.8 sodium channels situated in the peripheral nervous system, thereby intercepting pain signals prior to their transmission to the brain, providing efficacious pain alleviation free from risks of dependence. Trials conducted clinically showed a notable decrease in pain when contrasted with a placebo, accompanied by a well-received safety record featuring minor adverse effects like itching and muscle spasms.
Oral Solid Dosage Pharmaceutical Formulation Market Key Players: Which Companies Lead Industry Competition?
Major companies operating in the oral solid dosage pharmaceutical formulation market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc., Novartis AG, Hoffman-La-Roche Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim GmbH, Gilead Sciences, Amgen Inc., Teva Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Biogen Inc., Lonza Group, Catalent Inc., Ashland Inc., Piramal Pharma Solutions, Jubilant Pharmova, CordenPharma International
View The Full Oral Solid Dosage Pharmaceutical Formulation Market Report:
Oral Solid Dosage Pharmaceutical Formulation Market Regional Analysis And Leading Geography
North America was the largest region in the oral solid dosage pharmaceutical formulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral solid dosage pharmaceutical formulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model